Economy/Home · Economy

Onctic Therapeutics Receives Amendment Approval for Phase 3 Clinical Trial Plan of Zaqubo Tablet-based Helicobacter pylori Eradication Therapy

Onctic Therapeutics announced that it has received approval for an amendment to its Phase 3 clinical trial plan to evaluate the efficacy and safety of a triple therapy based on Zaqubo tablets (JP-1366, tegoprazan citrate) in patients positive for Helicobacter pylori. The amendment was approved on th

Oseong Kwon
Staff Reporter
5 min read
Onctic Therapeutics Receives Amendment Approval for Phase 3 Clinical Trial Plan of Zaqubo Tablet-based Helicobacter pylori Eradication Therapy
CBC News

Onctic Therapeutics announced that it has received approval for an amendment to its Phase 3 clinical trial plan to evaluate the efficacy and safety of a triple therapy based on Zaqubo tablets (JP-1366, tegoprazan citrate) in patients positive for Helicobacter pylori. The amendment was approved on the 2nd by South Korea's Ministry of Food and Drug Safety (MFDS).

The trial is a multicenter, randomized, double-blind, active-controlled, parallel-group, non-inferiority Phase 3 study evaluating the efficacy and safety of the JP-1366-based triple therapy in Helicobacter pylori-positive patients. It will be conducted at Incheon St. Mary's Hospital of the Catholic University of Korea and 23 other institutions, with a target enrollment of 414 subjects in total.

The objective of the trial is to demonstrate that the JP-1366-based triple therapy is non-inferior to a lansoprazole-based triple therapy as a first-line eradication treatment for Helicobacter pylori-positive patients. The investigational drug will be administered orally twice daily, in the morning and evening, preferably at the same time each day, before meals with water, for a total of two weeks.

The primary endpoint is the Helicobacter pylori eradication rate at least four weeks after completion of the investigational product administration. For the difference in eradication rates between treatment groups, a 97.5% one-sided confidence interval will be calculated using the Miettinen-Nurminen method; non-inferiority of the test group will be established if the lower bound of the confidence interval exceeds the non-inferiority margin of -0.1.

The clinical trial period is approximately 24 months from the date of Institutional Review Board approval, with an expected completion date of September 2, 2028. However, the company noted that the expected completion date follows the schedule in the clinical trial application and may be subject to change.

Zaqubo 20mg tablets received product approval from the Ministry of Food and Drug Safety in April 2024 and are the 37th domestically developed new drug to be launched. The company explained that this trial represents the approved Phase 3 IND for adding a Helicobacter pylori eradication therapy indication to the drug.

Meanwhile, the disclosure noted as an investment caution that the statistical probability of a clinical trial drug ultimately receiving approval as a pharmaceutical product is known to be around 10%. It also stated that the clinical trial and product approval process may yield results that fall short of expectations, raising the possibility that the company may change or abandon its commercialization plans.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.